License submitted to FDA for drug to help those with large B-cell lymphoma
A biologics license application has been submitted to the US Food and Drug Administration (FDA)…
As one of the leading causes of death worldwide, cancer receives great focus from the life sciences industry. Indeed, it’s the largest therapeutic focus area for biotech and pharma companies, which are working on a large number of therapeutic approaches, including small molecules, T cell therapies, and antibody therapies.
Global cancer drug sales are estimated to reach €221B by 2024. The top 10 blockbuster drugs are sold by big pharma companies, like Roche, Merck, AbbVie, and Bristol-Myers Squibb. Examples of blockbusters include Keytruda, Rituxan, and Herceptin.
Biotech companies are doing a fair bit of the work as well. Read on to keep up to date with the latest oncology research, discoveries, and market developments.
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportA biologics license application has been submitted to the US Food and Drug Administration (FDA)…
On this week’s podcast, we have three conversations: with Manfred Rüdiger, CEO of Ariceum Therapeutics;…
Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease…
A cancer drug from AstraZeneca and Daiichi Sankyo called Enhertu, that reduces the risk of…
Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic…
U.S. biopharma company Nuvation Bio Inc. says the Food and Drug Administration (FDA) has placed…
A clinical-stage biotech company that specializes in developing AI-driven immunotherapies has chosen its product candidate…
Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has…
Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in…
Data supporting the detection of minimal residual disease (MRD) has highlighted potential to provide an…
Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early…
Indian biotech start-up Immuneel Therapeutics has announced it has started patient dosing in a CAR-T…